AstraZeneca elontersen approved in the United States
因醉鞭名马幌
发表于 2023-12-22 19:55:51
306
0
0
On December 21st local time, AstraZeneca announced that its and Ionis company's eplontersen have been approved in the United States. Eplontersen is an antisense oligonucleotide (ASO) therapy for the treatment of hereditary thyroxine protein (TTR) mediated amyloidosis multiple neuropathy (ATTRv PN).
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Institution: Apple iPhone 16 Series Debuts in the United States, Sales Decrease Slightly YoY
- Comments from various sectors in the United States on non farm farming: Can 12000 yuan still be used for "American style downgrading"? The expectation of interest rate cuts has stabilized
- Comments from various sectors in the United States on non farm farming: Can 12000 yuan still be used for "American style downgrading"? The expectation of interest rate cuts has stabilized
- Meta will invest $10 billion to build a data center in Louisiana, USA
- The combination of AI and catering business has caused the stock price of this American company to skyrocket by over 30% in a day!
- The final agreement text of the US National Defense Authorization Act for fiscal year 2025 has been released, and the Biosafety Act has not been included
- Merck antifungal drug Noclof é l? New indications approved
- Just tonight! The last potentially explosive US data for 2024 has arrived
- Wal Mart stores nationwide enter Meituan, access Meituan distribution
- Starbucks union plans to hold strikes in three cities in the United States
